SCHEMBL701913

SCHEMBL701913

O=C1Nc2ccc(Cl)cc2C1=Cc1ccc(-c2ccc(C(=O)O)cc2F)o1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 9/20 0.60
PIM2 Q9P1W9 8/20 0.60
RPS6KA3 P51812 1/20 0.52
LRRK2 Q5S007 3/20 0.51
FLT3 P36888 2/20 0.50
PIM3 Q86V86 1/20 0.49
MEN1 O00255 3/20 0.48
POLB P06746 3/20 0.48
KMT2A Q03164 3/20 0.48
MAPT P10636 2/20 0.48
GAA P10253 1/20 0.48
PKM P14618 1/20 0.48
PPARG P37231 1/20 0.48
NCOA2 Q15596 1/20 0.48
NCOA1 Q15788 1/20 0.48
L3MBTL1 Q9Y468 2/20 0.47
TDP1 Q9NUW8 1/20 0.47
PTPN1 P18031 2/20 0.46
PTPN2 P17706 1/20 0.46
MITF O75030 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL701912 1.00 PIM1 (0.60) PIM1PIM2RPS6KA3LRRK2FLT3
SCHEMBL700262 0.93 PIM1 (0.68) PIM1PIM2RPS6KA3LRRK2FLT3
SCHEMBL700261 0.93 PIM1 (0.68) PIM1PIM2RPS6KA3LRRK2FLT3
SCHEMBL702072 0.89 PIM1 (0.59) PIM1PIM2RPS6KA3LRRK2FLT3
SCHEMBL702071 0.89 PIM1 (0.59) PIM1PIM2RPS6KA3LRRK2FLT3
SCHEMBL10091744 0.83 PIM1 (0.78) PIM1PIM2RPS6KA3FLT3PIM3
SCHEMBL31434329 0.83 PIM1 (0.78) PIM1PIM2RPS6KA3FLT3PIM3
SCHEMBL700234 0.82 PIM1 (0.66) PIM1PIM2RPS6KA3LRRK2FLT3
SCHEMBL700233 0.82 PIM1 (0.66) PIM1PIM2RPS6KA3LRRK2FLT3
SCHEMBL702181 0.82 PIM1 (0.90) PIM1PIM2RPS6KA3LRRK2FLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120190669-A1 OXINDOLE COMPOUNDS CYLENE PHARMACEUTICALS, INC. (US) 2012-07-26 US disclosed
US-8124649-B2 Oxindole compounds CYLENE PHARMACEUTICALS, INC. (US) 2012-02-28 US disclosed
EP-2307421-A1 OXINDOLE COMPOUNDS Cylene Pharmaceuticals, Inc. (US) 2011-04-13 EP disclosed
US-20100041635-A1 OXINDOLE COMPOUNDS CYLENE PHARMACEUTICALS, INC. 2010-02-18 US disclosed
WO-2010002933-A1 OXINDOLE COMPOUNDS CYLENE PHARMACEUTICALS, INC. (US) 2010-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100041635-A1 OXINDOLE COMPOUNDS FLT3, PIM1, PIM2 PIM1 2/4885PIM2 3/4885RPS6KA3 290/4885
US-20120190669-A1 OXINDOLE COMPOUNDS FLT3, PIM1, PIM2 PIM1 2/4885PIM2 3/4885RPS6KA3 290/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.